A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone

Stopped early

Conditions studied: Idiopathic Thrombocytopenia Purpura

In brief

In this prospective and retrospective chart review, investigators will evaluate the response rates and duration of response for patients with relapsed and refractory idiopathic thrombocytopenic purpura (ITP) who have been treated with rituximab and repeated courses of dexamethasone. Investigators will also evaluate observed toxicities of the combination, and characteristics associated with response.

Key facts

Study ID

NCT02050581

Run by

Weill Medical College of Cornell University

People needed

72

Starts

2011-01-01

Last updated by the study team

2018-07-16

Who can join

Age: 3 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must be diagnosed with ITP.
• Subjects must be 3 years old or older
• Subjects must have a platelet count less than 40,000/uL at initiation of treatment regimen or inability to discontinue maintenance treatments such as intravenous immunoglobulin (IVIG), corticosteroids, azathioprine, and/or a thrombopoietin receptor agonist.

You may not qualify if…

• Subjects who have not been diagnosed with ITP. 2 Subjects who are younger than 3 years old 3. Subjects who have a medical condition that would be adversely affected by high dose steroids

Where it is running

• New York Presbyterian Hospital Weill Cornell Medical College — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.